09.12.2015 • NewsElaine BurridgeRochecancer

Roche Agrees Cancer Partnership with SQZ Biotech

Roche and SQZ Biotech are working together to develop a cell therapy platform that would empower patients’ own immune cells to fight a broad range of cancers.

SQZ’s pioneering technology is based on introducing proteins, or antigens, into patients’ B cells which will then help activate killer T cells to attack the cancer. SQZ said its novel approach, which seeks to target tumors more effectively, has the potential to overcome many of the shortcomings of current cell-based therapies.

Under the deal, the US biotech firm, a spin-out of the Massachusetts Institute of Technology (MIT), will get more than $500 million in upfront and potential clinical, regulatory and sales milestone-based payments as well as royalties on potential future products.

SQZ Biotech is backed by Polaris Venture Partners and 20/20 Healthcare Partners.

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.